| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Net revenues | 8,292,362 | 10,837,363 | 9,085,826 | 9,848,849 |
| Cost of products sold | 988,760 | 2,011,389 | 1,323,013 | 1,710,944 |
| Selling and marketing | 4,433,831 | 4,223,647 | 4,397,480 | 4,248,401 |
| Research and development | 1,253,367 | 1,468,399 | 1,306,095 | 1,059,187 |
| General and administrative | 2,572,066 | 2,874,922 | 2,675,380 | 2,757,148 |
| Amortization | 1,009,598 | 1,006,484 | 1,078,290 | 1,099,857 |
| Total costs and expenses | 10,257,622 | 11,584,841 | 10,780,258 | 10,875,537 |
| Operating loss | -1,965,260 | -747,478 | -1,694,432 | -1,026,688 |
| Interest income | 131,583 | 127,489 | 69,190 | 61,841 |
| Other income - insurance proceeds | 0 | - | 237,089 | - |
| Interest expense | 109,699 | 109,547 | 137,374 | 126,347 |
| Loss before income taxes | -1,943,376 | -729,536 | -1,525,527 | -1,091,194 |
| Income tax expense | 5,670 | 5,671 | 11,442 | 11,443 |
| Net loss | -1,949,046 | -735,207 | -1,536,969 | -1,102,637 |
| Net loss (income) at subsidiary attributable to noncontrolling interests | -8,282 | 5,533 | 7,112 | -17,025 |
| Net loss attributable to common shareholders | -1,940,764 | -740,740 | -1,544,081 | -1,085,612 |
| Basic (in shares) | 14,958,534 | 14,960,596 | 14,052,754 | 14,118,091 |
| Basic (in usd per share) | -0.13 | -0.05 | -0.11 | -0.08 |
| Diluted (in shares) | 14,958,534 | 14,960,596 | 14,052,754 | 14,118,091 |
| Diluted (in usd per share) | -0.13 | -0.05 | -0.11 | -0.08 |
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)